To discover ways to prevent or delay resistance to cancer therapies, a new NCI-funded center at OHSU is exploring how acute myeloid leukemia cells evolve and adapt.
Posts Tagged ‘AML’
Targeted cancer therapies work by singling out gene mutations that drive tumor growth, then using a drug to block the effects of the mutant gene. But tumors consist of millions of cells that may collectively harbor hundreds of different “driver” mutations. That means therapies for some cancers will have to target more than one mutation at a time to be successful. To help solve the problem, researchers at Oregon Health & Science University devised … Read More
The best available treatment for acute myeloid leukemia is a drug combination established more than 30 years ago. And today less than a third of newly diagnosed AML patients survive beyond five years. An ambitious clinical trial announced this week aims to speed up the search for new treatments by matching patients with one of several different drugs selected to block a specific tumor mutation or signaling pathway.
New findings open a path for developing desperately needed therapies for the most frequently diagnosed leukemia in adults. Leukemia paves the way for its deadly advance by manipulating the micro-environment within the bone marrow, triggering changes that suppress healthy, blood-forming stem cells while favoring the growth of cancer. The loss of hematopoietic stem cells results in bleeding, shortness of breath, fatigue, and infections. Researchers led by OHSU’s Peter Kurre, M.D., now have uncovered one of the … Read More
Nine drug companies and six universities have now joined an unusual collaboration to break the logjam in research on acute myeloid leukemia (AML), a blood cancer lacking effective treatments. Less than 25 percent of newly diagnosed patients survive beyond five years with a standard of care based on 40-year-old chemotherapy agents. The research initiative, Beat AML, is supplying a stock of drug candidates and treatment ideas, a dozen of which were presented on Dec. 5-8 at … Read More
A preclinical study led by an OHSU Knight Cancer Institute physician may point the way to more effective tests for recurrence of acute myeloid leukemia. Nearly half of patients diagnosed with AML will eventually experience a relapse, even with the best available treatment. And those patients must undergo bone marrow biopsies to detect relapses, says Peter Kurre, M.D., who specializes in pediatric hematology/oncology and blood disorders. Bone marrow biopsies are uncomfortable for the patient … Read More